
Browsing restrictions can be lifted for a fee.
0.18%
Procept biorobotics corporation
0.05%
Avg of Sector
-0.31%
S&P500

Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2026Q1 | ||||
| 2026Q2 | ||||
| 2026Q3 | ||||
| 2026Q4 | ||||
| 2027Q1 |
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2025Q4 | |||||||
| 2025Q3 | |||||||
| 2025Q2 | |||||||
| 2025Q1 |
The most recent financial report for Procept biorobotics corporation (PRCT) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating PRCT's short-term business performance and financial health. For the latest updates on PRCT's earnings releases, visit this page regularly.
According to the latest financial report, Procept biorobotics corporation (PRCT) reported an Operating Profit of -31.04M with an Operating Margin of -40.64% this period, representing a decline of 57.49% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, Procept biorobotics corporation (PRCT) announced revenue of 76.38M, with a Year-Over-Year growth rate of 11.94%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
As of the end of the reporting period, Procept biorobotics corporation (PRCT) had total debt of 78.48M, with a debt ratio of 0.15. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
At the end of the period, Procept biorobotics corporation (PRCT) held Total Cash and Cash Equivalents of 286.5M, accounting for 0.56 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, Procept biorobotics corporation (PRCT) did not achieve the “three margins increasing” benchmark, with a gross margin of 60.6%%, operating margin of -40.64%%, and net margin of -39.1%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess PRCT's profit trajectory and future growth potential.
According to the past four quarterly reports, Procept biorobotics corporation (PRCT)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.53. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
Procept biorobotics corporation (PRCT)'s Free Cash Flow (FCF) for the period is -12.18M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 63.72% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
The latest valuation data shows Procept biorobotics corporation (PRCT) has a Price-To-Earnings (PE) ratio of -13.94 and a Price/Earnings-To-Growth (PEG) ratio of -0.35. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.